ArticleNature communications2017
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 74 citations in OpenAlex.
- Targeting the PI3K/AKT/mTOR pathway in gastrointestinal cancers: a comprehensive review of mechanisms, preclinical evidence, and clinical challenges.Medical oncology (Northwood, London, England) · 2026Review
- Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.Nature communications · 2026Article
- Recurrent somatic copy number alterations in resected cerebral cavernous malformations.Human genomics · 2025Article
- Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.Research square · 2025Article
- BeyondmedRxiv : the preprint server for health sciences · 2025Article
- Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients.Cancers · 2025Article
- Construction of a prognostic risk model for clear cell renal cell carcinomas based on centrosome amplification-related genes.Molecular genetics and genomics : MGG · 2025Article
- Article
- SETD2 and EZH2: Two epigenetic drivers of prostate cancer.Journal of Cancer · 2025Review
- Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1-Dependent Regulation of MAD2L1 mRNA Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Organismal metabolism regulates the expansion of oncogenic PIK3CA mutant clones in normal esophagus.Nature genetics · 2024Article
- Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.Nature communications · 2024Article
- Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Whole-genome doubling is a double-edged sword: the heterogeneous role of whole-genome doubling in various cancer types.BMB reports · 2024Review
- Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.Frontiers in oncology · 2024Review
- Article
- Genetic Characterization of Ovarian Tumor Tissues from Patients with Epithelial Ovarian Cancer in a Philippine Tertiary Hospital: A Descriptive Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Mitochondrial respiration inhibitor enhances the anti-tumor effect of high-dose ascorbic acid in castration-resistant prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Modest increase of KIF11 expression exposes fragilities in the mitotic spindle, causing chromosomal instability.Journal of cell science · 2022Article
- When, where and which PIK3CA mutations are pathogenic in congenital disorders.Nature cardiovascular research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 9 institutions in 3 countries.
Inma M BerenjenoUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK. i.berenjeno@ucl.ac.uk.
Roberto PiñeiroUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Sandra D CastilloUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Wayne PearceUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Nicholas McGranahanThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals, 72 Huntley Street, London, WC1E 6DD, UK.
Sally M DewhurstThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals, 72 Huntley Street, London, WC1E 6DD, UK.
Valerie MenielEuropean Cancer Stem Cell Research Institute, Cardiff University, Cardiff, CF24 4HQ, UK.
Nicolai J BirkbakThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals, 72 Huntley Street, London, WC1E 6DD, UK.
Evelyn LauUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Laurent SansregretUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Daniele MorelliUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Nnennaya KanuThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals, 72 Huntley Street, London, WC1E 6DD, UK.
Shankar SrinivasDepartment of Physiology Anatomy and Genetics, University of Oxford, Oxford, OX1 2JD, UK.
Mariona GrauperaVascular Signalling Laboratory, Institut d´Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, 08908, Spain.
Victoria E R ParkerInstitute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
Karen G MontgomeryCancer Biology and Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, 3000, VIC, Australia.
Larissa S MonizUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK.
Cheryl L ScudamoreMary Lyon Centre, MRC Harwell, Harwell, OX11 0RD, UK.
Wayne A PhillipsCancer Biology and Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, 3000, VIC, Australia.ORCID http://orcid.org/0000-0002-7961-638X
Robert K SempleInstitute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
Alan ClarkeEuropean Cancer Stem Cell Research Institute, Cardiff University, Cardiff, CF24 4HQ, UK.
Charles SwantonUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK. charles.swanton@crick.ac.uk.
Bart VanhaesebroeckUCL Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street London, London, WC1E 6DD, UK. bart.vanh@ucl.ac.uk.
CRUK Lung Cancer Centre of Excellence · GBThe Francis Crick Institute · GBCardiff University · GBPeter MacCallum Cancer Centre · AUUniversity of Cambridge · GBComplejo Hospitalario Universitario de Santiago · ESInstitut d'Investigació Biomédica de Bellvitge · ESMary Lyon Centre at MRC Harwell · GBUniversity of Oxford · GB
Funding
Biotechnology and Biological Sciences Research Council BB/F011512/1Biotechnology and Biological Sciences Research Council BB/J00989X/1Cancer Research UK 15965Cancer Research UK 17786Cancer Research UK 19310Cancer Research UK 20466Cancer Research UK 24956Cancer Research UK C1295/ A15937Cancer Research UK C23338/A15965Medical Research Council MRC_MC_UU_12012/5Medical Research Council MR/P014712/1Wellcome TrustWellcome Trust 097721/Z/11/ZWellcome Trust 103788/Z/14/ZWellcome Trust WT098498
Abstract
Mutations in PIK3CA are very frequent in cancer and lead to sustained PI3K pathway activation. The impact of acute expression of mutant PIK3CA during early stages of malignancy is unknown. Using a mouse model to activate the Pik3ca
Indexed as
Gene AmplificationGenomeAnimalsBreast NeoplasmsCentrosomeClass I Phosphatidylinositol 3-KinasesCohort StudiesFemaleHumansMaleMiceMice, Inbred C57BLMutationOncogenesPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, humanPik3ca protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.